![With 20 Agents, 803 Trials, and 166,736 Patient Slots, Is Pharma Investing Too Heavily in PD-1 Drug Development?](https://cdn.cancerletter.com/media/2016/10/pd1-TAXI-small-web.jpg)
![With 20 Agents, 803 Trials, and 166,736 Patient Slots, Is Pharma Investing Too Heavily in PD-1 Drug Development?](https://cdn.cancerletter.com/media/2016/10/pd1-TAXI-small-web.jpg)
Cover Story
Free
By Laura Brawley
Pharmaceutical companies are betting big on cancer immunotherapies that rely on the PD-1 protein and its ligands, PD-L1 and PD-L2, to initiate an immune response.
Trending Stories
- Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot
- NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission